New treatment approach for pancreatic cancer using anti-complement therapy
Anti-Complement Immunotherapy for Pancreatic Cancer
This study is exploring a new treatment for pancreatic cancer that works by boosting the immune system's ability to fight the disease, and it aims to find out if combining this treatment with radiation can help improve outcomes for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10984451 on NIH RePORTER |
What this research studies
This research investigates a novel immunotherapy aimed at pancreatic cancer, specifically targeting the complement system that contributes to the disease's aggressive nature. By understanding how the tumor microenvironment influences cancer progression, the study seeks to block complement activation, which may help improve immune response against tumors. The research utilizes a unique mouse model to track tumor growth and assess the effectiveness of this therapy in combination with radiotherapy. Patients may benefit from insights gained that could lead to new treatment options for pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options.
Not a fit: Patients with early-stage pancreatic cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While the approach of targeting the complement system in cancer is emerging, this specific application in pancreatic cancer is relatively novel and has not been extensively tested.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Bell, Brett I — Albert Einstein College of Medicine
- Study coordinator: Bell, Brett I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.